Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
August 19, 2021 22:20 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten...
Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
August 19, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, announced today that it intends to offer and sell, subject to market...
Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:01 ET
|
Progenity, Inc.
Announced successful completion of the validation study PRO-104 for the Preecludia™ rule out test for preeclampsia and achievement of the primary endpoint of the study protocol Recently achieved...
Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update
August 05, 2021 16:05 ET
|
Progenity, Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on...
Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
July 29, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™...
Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
June 30, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July...
Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
June 17, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory...
Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
June 15, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder...
NASDAQ: PROG Investor Notice: Update in Lawsuit against Progenity, Inc. announced by Shareholders Foundation
June 15, 2021 07:10 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that an update in the lawsuit that is pending for certain investors in NASDAQ: PROG shares. Investors, who...
Progenity Announces $40 Million Private Placement
June 10, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive securities...